

BEST AVAILABLE COPY

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/10, 15/62, 15/81, C07K 14/395		A2	(11) International Publication Number: WO 97/44447 (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/US97/07338			(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 2 May 1997 (02.05.97)			
(30) Priority Data: 60/017,016 3 May 1996 (03.05.96) US Not furnished 1 May 1997 (01.05.97) US			Published <i>Without international search report and to be republished upon receipt of that report.</i>
(71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 124 Mount Auburn Street, Cambridge, MA 02138-5701 (US).			
(72) Inventors: PTASHNE, Mark; 85 Sparks Street, Cambridge, MA 02138 (US). LU, Xiangyang; 15 Beacon Street, No. 3, Somerville, MA 02143 (US). WU, Yibing; 7 Divinity Avenue, Cambridge, MA 02138 (US).			
(74) Agent: JARRELL, Brenda, Herschbach; Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109-4000 (US).			

(54) Title: TRANSCRIPTIONAL ACTIVATION SYSTEM, ACTIVATORS, AND USES THEREFOR



(57) Abstract

The present invention describes novel transcriptional activators and activation systems. The activators of the present invention comprise a DNA binding moiety linked to a short peptide of novel sequence. Preferably, the peptide is substantially hydrophobic. Preferred peptides include at least one aromatic amino acid. The present invention also provides improved transcriptional activation systems, useful for the identification and characterization of protein-protein interactions. The invention also describes the production and use of certain TBP mutants that enhance transcriptional activation by some activators.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

TRANSCRIPTIONAL ACTIVATION SYSTEM, ACTIVATORS, AND USES
THEREFOR

Related Application

5 The present application is a Continuation-in-part of co-pending application number 60/017,016, filed May 3, 1996, the entire contents of which are incorporated herein by reference.

Government Support

10 The work described herein was supported by United States government grant number GM32308-14 from the National Institutes of Health. The United States government may have certain rights in the invention.

Background of the Invention

15 Gene activation requires interaction of DNA-bound activators with proteins binding near the transcription start site of a gene (Ptashne, *Nature* 335:983, 1988). In eukaryotes, activation of RNA polymerase II genes requires many transcription factors in addition to RNA polymerase. Transcriptional activators have been shown to contact one or another of these transcription factors, including TATA-binding
20 protein (TBP), TBP-associated factors (TAFs), TFIIB, and TFIID (Roeder, *Trends Biochem. Sci.* 16:402, 1991; Zawel et al., *Prog. Nucl. Acids Res. Mol. Biol.* 44:67, 1993; Conaway et al., *Annu. Rev. Biochem.* 62:161, 1993; Hoey et al., *Cell* 72:247). Thus, it has been proposed that transcription initiation involves a multistep assembly process, various steps of which might be catalyzed by activators
25 (Buratowski et al., *Cell* 56:549, 1989; Choy et al., *Nature* 366:531, 1993).

Some transcriptional activators are thought to recruit one or more transcription factors to the DNA, to cause crucial conformational changes in target proteins and thereby to facilitate the complex process of assembling the transcriptional machinery, or both (Lin et al., *Cell* 64:971, 1991; Roberts et al.,
30 *Nature* 371:717, 1994; Hori et al., *Curr. Op. Genet. Dev.* 4:236, 1994). Also, given the observation that yeast RNA polymerase II is associated with several

transcription factors, in a complex termed the "holoenzyme", it has been proposed that some transcriptional activators might function by recruiting the holoenzyme complex to DNA (Koleske et al., *Nature* 368:466, 1994; Kim et al., *Cell* 77:599, 1994; Carey, *Nature* 368:402, 1994).

5 Transcriptional activation has been much studied both in the context of controlling gene expression in cells, for example so that principles of gene activation can be employed in genetic therapies, and as an experimental tool for analysis of protein-protein interactions in cells (Fields et al., *Nature* 340:245, 1989; Gyuris et al., *Cell* 75:791, 1993). One difficulty that has been encountered in the use and

10 analysis of transcriptional activation systems, however, is that over-expression of transcriptional activators in cells typically inhibits gene expression, sometimes with dire results on the cells. This effect, termed "squelching", apparently represents the titration of a transcription factor by the over-expressed transcriptional activator (Gill et al., *Nature* 334:721, 1988). Another difficulty that has been encountered

15 specifically in the protein-protein interaction applications is that useful controls are often unavailable, so that spurious results are often observed. Also, the protein-protein interaction systems are typically not useful for identification of proteins that interact with transcriptional activators themselves. Given that transcriptional activators represent a significant fraction of all known proteins, this limitation of

20 existing systems presents a serious problem.

There remains a need for the identification of novel transcriptional activators and improved transcriptional activation systems. In particular, there is a need for strong transcriptional activators that do not "squelch" other known activators, and for protein-protein interaction systems useful for identifying interaction partners of

25 transcriptional activators.

Summary of the Invention

The present invention provides novel transcriptional activators. In particular, the invention provides activators in which a short peptide having activating capability

30 is linked to a DNA binding domain. The peptides do not correspond to fragments of known transcriptional activators (that is, their sequences are not found in the

SwissProt database). Moreover, the peptides apparently activate transcription by a novel mechanism as they do not squelch known activators when they are over expressed in yeast. Without wishing to be bound by any particular theory, we propose that these activators function by interacting with a component of the RNA 5 polymerase II holoenzyme; this hypothesis is consistent with the observation that the only other transcriptional activator known not to squelch is Gal11, which is part of the holoenzyme (see Barberis et al., *Cell*, 81:359, 1995). The present invention also provides methods of identifying, characterizing, and using such novel transcriptional activators. In particular, the invention provides methods of activating transcription 10 by providing such a novel activator to a cell.

The present invention also provides novel transcriptional activation systems, each based on the idea of exploiting non-conventional transcriptional activators. The systems described herein utilize holoenzyme components, or factors that interact therewith, in a way that provides advantages over known transcriptional activation 15 systems. For example, we provide protein-protein interaction systems that utilize Gal11 and/or Gal11P to overcome some of the above-mentioned difficulties with standard di-hybrid and interaction trap systems.

The present invention also provides novel TBP mutants that increase transcriptional activation by certain activators. The particular TBP mutants 20 described enhance activation by Gal11 more than they enhance activation by Gal4 region II. The invention also provides methods of identifying, characterizing, and using such TBP mutants.

Description of the Drawings

25 Figure 1 shows transcriptional activation by an inventive peptide activator, but not by peptides of the same composition but scrambled sequence.

Figure 2 presents β -galactosidase assays that demonstrate the contributions of certain Gal4-DNA binding domain residues to activation by peptide LS201.

Figure 3 shows transcriptional activation by an inventive peptide linked to the 30 Pho4 DNA binding domain.

Figure 4 depicts the purification scheme used for yeast holoenzyme preparations.

Figure 5 shows *in vitro* transcriptional activation by Gal4-LS201 in a yeast nuclear extract.

5 Figure 6 shows *in vitro* transcriptional activation by Gal4-LS201 on the yeast holoenzyme.

Figure 7 is a schematic of a standard protein-protein interaction transcriptional activation assay.

10 Figure 8 is a schematic of a protein-protein interaction transcriptional activation assay employing Gal11 as the activation domain.

Figure 9 is a schematic of the "three-component" protein-protein interaction transcriptional activation assay.

Description of Preferred Embodiments

15 **Novel Transcriptional Activators**

Typical naturally-occurring transcriptional activators are modular proteins that have separable DNA binding and transcriptional activation regions (Ptashne, *Nature* 335:983, 1988). The present invention provides novel transcriptional activators, comprising a DNA binding moiety linked to a short, substantially hydrophobic 20 peptide. The peptide is approximately 6-25 amino acids in length, and preferably is about 8-17 amino acids long. In particularly preferred embodiments, the peptide is 13 amino acids long.

The activating peptides of the present invention have amino acid sequences that do not correspond to a portion of a known transcriptional activation domain. 25 Sequences of known transcriptional activation domains are available in the literature and in computer databases such as, for example, GenBank, PIR, SwissProt, NCBI, Prosite. One of ordinary skill in the art can therefore readily determine whether a particular peptide corresponds to a portion of a known activating region.

Preferred peptides of the present invention include at least approximately 30 25%, preferably at least approximately 50%, hydrophobic amino acids. That is, at least approximately 25-50% of the amino acid residues in preferred peptides of the

present invention are alanine (A), leucine (L), isoleucine (I), valine (V), proline (P), phenylalanine (F), tryptophan (W), or methionine (M). Alternatively or additionally, preferred peptides include at least one aromatic residue (i.e., F, W, or tyrosine (Y)). Particularly preferred peptides also do not include any positively charged residues, at 5 least not near the terminus farthest from the DNA-binding domain.

Particularly preferred peptides of the present invention are presented in Table 1 (identified with "LS"). Of the peptides presented in Table 1, those that, when expressed in yeast cells, activate β -galactosidase activity to at least about $\frac{1}{2}$ the level observed with full-length Gal4 are preferred transcriptional activation peptides 10 according to the present invention. For example, peptides LS4 (QLPPWL); LS8 (QFLDAL); LS11 (LDSFYV); LS12 (PPPPWP); LS17 (SWFDVE); LS19 (QLPDLF); LS20 (PLPDLF); LS21 (FESDDI); LS24 (QYDLFP); LS25 (LPDLIL); LS30 (LPDFDP); LS35 (LFPYSL); LS51 (FDPFNQ); LS64 (DFDVLL); LS102 (HPPPPI); LS105 (LPGCFF); LS106 (QYDLFD); LS120 (YPPPPF); LS123 15 (PLPPF); LS135 (LPPPWL); LS136 (VWPPAV); LS152 (DPPWYL); LS153 (LY); LS158 (FDPFGL); LS160 (PPSVNL); LS201 (YLLPTCIP); LS202 (LQVHNST); LS203 (VLDFTPFL); LS206 (HHAFYEIP); LS212 (PWYPTPYL); LS223 (YLLPFLPY); LS225 (YFLPLLST); LS232 (FSPTFWAF); LS241 20 (LIMNWPTY) are preferred inventive peptides. Particularly preferred are those that activate at least approximately as well as does full-length Gal4 (e.g., LS4, LS11, LS12, LS17, LS19, LS20, LS35, LS64, LS102, LS123, LS135, LS136, LS160, LS201, LS206, LS223, LS225 AND LS203).

The peptides of the present invention can be linked to any available DNA binding moiety to create a transcriptional activator of the present invention. For 25 example, the peptides can be linked to a DNA-binding polypeptide (e.g., an intact protein that does not function as a transcriptional activator but binds to DNA, or any portion of a DNA-binding protein that retains DNA-binding activity) (see, for example, Nelson, *Curr. Op. Genet. Dev.* 5:180, 1995), a DNA-binding peptide derivative (see, for example, Wade et al., *JACS* 114:8784, 1992; Mrksich et al., 30 *Proc. Natl. Acad. Sci. USA* 89:7586, 1992; Mrksich et al., *JACS* 115:2572, 1993; Mrksich et al., *JACS* 116:7983, 1994), an anti-DNA antibody (see, for example,

Stollar, *Faseb J.*, 8:337, 1994), a DNA intercalation compound (e.g., p-carboxy methidium, p-carboxy ethidium, acridine and ellipticine), a groove binder (e.g., netropsin, distamycin, and actinomycin; see, for example, Waring et al., *J. Mol. Recog.* 7:109, 1994), or a nucleic acid capable of hybridizing, to form a duplex or a 5 triplex, with a target DNA sequence (see, for example Gee et al., *Am. J. Med. Sci.* 304:366, 1992). Preferably, the peptides are linked to a sequence-specific DNA-binding moiety, so that they can be targeted to a selected DNA site from which to activate transcription.

Any available linkage (e.g., covalent bonding, hydrogen bonding, 10 hydrophobic association, etc.) may be utilized to associate the peptide to a DNA binding moiety, so long as the DNA-binding activity of the DNA-binding moiety and the transcriptional activation activity of the peptide are preserved. The linkage between the activating peptide and the DNA binding domain may be direct or may alternatively may be mediated by a "linkage factor". A linkage factor is any entity 15 capable of mediating a specific association between the DNA binding moiety and the activating peptide while preserving the activities of both. The term "specific association" has its usual meaning in the art: an association that occurs even in the presence of competing non-specific associations. The concept of linkage factors is known in the field of transcriptional activation and its scope and significance will 20 readily be appreciated by those of ordinary skill in the art. To name but one example, rapamycin acts as a linkage factor when it mediates interactions between a DNA binding moiety that includes, for example, FK506 binding protein and a transcriptional activating moiety that includes a cyclophilin (Belshaw et al., *Proc. Natl. Acad. Sci. USA* 93:4604, 1996).

25 Preferred transcriptional activators of the present invention comprise a small, substantially hydrophobic peptide as described above, linked to a DNA-binding polypeptide that preferably has sequence-specific DNA binding activity. In particularly preferred embodiments, the peptide is linked to the DNA binding domain (i.e., a sufficient portion of the protein to recognize DNA but not to have 30 transcriptional regulatory activity in the absence of the attached peptide) of a transcriptional regulatory protein (see, for example, Klug, *Ann. NY Acad. Sci.*

758:143, 1995). The choice of DNA binding domain will of course depend on the gene intended to be activated; the DNA binding domain should recognize a site positioned relative to the transcriptional start site of the gene that the activator can affect transcription. Preferably, the site should be within approximately 250-1000

5 basepairs of the transcription start site, although this is not strictly required as, particularly in higher mammalian systems (e.g., human), transcriptional activators are known to be effective when bound several thousand basepairs away (upstream or downstream) of the transcription start site (see, for example, Serneza, *Hum. Mutat.* 3:180, 1994; Hill et al. *Cell* 80:199, 1995).

10 The transcriptional activators of the present invention may be prepared by any available methods including, for example, recombinant nucleic acid methodologies (see, for example, Sambrook et al., *Molecular Cloning: a Laboratory Manual*, 2nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989; Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press, San

15 Diego, Ca, 1990; Erlich et al., *PCR Technology: Principles and Applications for DNA Amplification*, Stockton Press, New York, NY, 1989, each of which is incorporated herein by reference), synthetic chemistry (see, for example, Bodansky et al., *The Practice of Peptide Synthesis*, Springer-Verlag, New York, NY, 1984; Atherton et al., *Solid Phase Peptide Synthesis: a Practical Approach*, IRL Press at

20 Oxford University, England, 1989, each of which is incorporated herein by reference), or other techniques capable of linking the desired moieties to one another.

As described in Example 1, we prepared our transcriptional activators by using PCR to link random oligonucleotides, either 18 or 24 nucleotides long, to

25 DNA encoding the Gal4 DNA binding domain, so that hybrid genes were produced that encoded a fusion protein consisting of a Gal4 DNA binding domain and either a 6-mer or 8-mer peptide. The hybrid genes were under control of a yeast promoter, so that the fusion proteins were expressed in yeast. We screened this library of potential transcriptional activators for those that could stimulate transcription of a β -

30 galactosidase reporter gene that had upstream Gal4 binding sites, and also compared the activators' activity to that of full-length Gal4. After screening fewer than

approximately 200,000 colonies, we had identified close to 200 activators. Thus, at least about 0.1% of our hybrid genes resulted in fusion proteins with transcriptional activation activity; about 5% of these activators stimulated transcription more effectively than did full-length Gal4 (see Table 1). Particularly preferred

5 transcriptional activators of the present invention, therefore, activate transcription at least as effectively as does a known activating region linked to the same DNA binding moiety as is employed in the novel transcriptional activator. Such transcriptional activators, that effectively stimulate transcription through an activation domain only approximately 6-8 amino acids long, have not previously been

10 described.

We further characterized our new transcriptional activators by determining the nucleotide sequence of their hybrid genes, and deducing therefrom the amino acid sequence of the encoded proteins (see Example 1). Although we found no obvious consensus sequence among our activator peptides, we noticed that all were

15 substantially hydrophobic. Specifically, each of the peptides had at least about 30% hydrophobic residues. The least hydrophobic peptides, LS106 and LS202, had 33% and 29% hydrophobic residues; the most hydrophobic had 100% hydrophobic residues (LS123, LS135, LS136, LS235). Overall, of 109 peptides sequenced, a total of 682 residues were analyzed, 466 of which (68%) were hydrophobic. Also,

20 approximately 90% of the peptides we analyzed included at least one aromatic residue. Only one peptide LS215, had a basic residue. LS215 is one of the weaker activators we identified.

We have observed that certain residues of the Gal4 DNA binding domain to which our peptides are linked contribute to the observed transcriptional activation

25 (see Examples 1 and 2). Specifically, we have found that, for at least the LS201 activator, deletion of any one of the last five residues (residues 96-100) of the Gal4 DNA binding domain reduces activation activity about 10-1000 fold. Furthermore, substitution of either Phe97 or Val98 with Ala also reduces transcriptional activation about 40-150 fold. On the other hand, substitution of either Gln99 or Asp100 with

30 Val has no effect on transcriptional activation. Also, Gal4 residues outside of 96-100 are not required for transcriptional activation (see Example 2).

The results presented in Example 2 demonstrate that the present invention actually describes three different set of activator peptides: i) those listed in Table 1; ii) peptides having an amino acid sequence identical to those listed in Table 1 except also including Gal4 DNA binding domain residues 96-100 (or 97-100); and iii) 5 peptides having an amino acid sequence identical to those of set ii except that one or both of Gln99 and Asp100 has been substituted with another amino acid, preferably an Ala. Of these three sets, preferred activator peptides are those that stimulate transcription at least half as effectively as does full-length Gal4 in a side-by-side comparison, as described herein. Particularly preferred peptide activators of the 10 present invention consist of Gal4 residues 96-100 (with or without substitutions at residues 99 and/or 100) plus either 6 or 8 additional, primarily hydrophobic residues. Accordingly, particularly preferred peptide activators are 11 or 13 amino acids long. Most preferred are 11- or 13- amino acid residues formed by linking one of the Table 1 peptides to Gal4 residues 96-100.

15 In order to further characterize our novel transcriptional activators, we assayed their ability to squelch activation by other transcriptional activators. A variety of natural activators, including a subset of mammalian transcriptional activators, have been observed to squelch transcriptional activation by Gal4 and Gcn4 when these natural activators are expressed in yeast (see, for example, Gill et al., *Nature* 334:721, 1988). Many of these activators have several acidic residues 20 and have been called "acidic" transcriptional activators (see, for example, Ma et al., *Cell* 51:113, 1987). For the purposes of the present application, we define an "acidic transcriptional activator" as any activator that, when expressed in yeast, squelches activation by Gal4 and/or Gcn4. The squelching phenomenon is believed 25 to result from competition by the activators (i.e., the test activator and Gal4 or Gcn4) for the same interaction target. If this model is correct, our data indicate that our novel transcriptional activators do not interact with the same target as do these acidic activators. Specifically, our new activators do not squelch activation by Gal4 (see Example 1).

30 As described in Example 1, we assayed the ability of our new transcriptional activators to squelch Gal4 activation by over-expressing the activators in a yeast cell.

The specific method we employed is only one of many possible ways to overexpress a protein in yeast. In general, over-expression of transcriptional activators in yeast can be accomplished, for example, by introducing the activator gene into the cells on a high copy-number plasmid such as a 2μ vector. Alternatively or additionally, the 5 activator gene can be introduced into the cell after being linked to a promoter that naturally directs, or can be induced to direct, high levels of transcription in yeast. Exemplary high-expression promoters include Gal1/10, Adh, actin, etc.

Furthermore, similar squelching assays can be designed and performed to detect the ability of our transcriptional activators to interfere with the activity of any 10 known transcriptional activator, in any desired experimental system. For example, we have tested our activators for their ability to squelch activation by Gal11, a protein that, when recruited to DNA through linkage to a DNA binding moiety, activates transcription as effectively as any known activator but does so through a mechanism distinct from that of the acidic activators and does not squelch their 15 activity (see Barberis et al., *Cell* 81:359, 1995, incorporated herein by reference). As shown in Example 1, our new transcriptional activators do not squelch Gal11 activation. Thus, the present invention provides a novel class of transcriptional activators, unique in structure, activity characteristics, and method of identification. Each of these unique aspects is encompassed by the present invention.

20 We have also assayed the ability of our activator peptides to stimulate transcription *in vitro*. As described in Example 3, we find that an activator consisting of the Gal4 DNA binding domain (1-100) linked to peptide LS201 stimulates transcription in a yeast nuclear extract, and also appears to stimulate transcription in the presence of only the yeast holoenzyme. These findings lend 25 support to our hypothesis that the present peptide activators constitute a novel class of transcriptional regulators that interact directly with the general transcription machinery.

One of ordinary skill in the art will readily appreciate that we have performed our transcriptional activator screen, and many of our analyses, in yeast primarily 30 because of the simplicity of the system, and the demonstrated usefulness of information obtained from a yeast system in understanding mammalian, and

particularly human, transcription. Many yeast transcriptional activators also function in higher systems, including human, and vice versa. The above-described screen for transcriptional activators can readily be repeated in other systems (e.g., in mammalian cells, preferably human cells), by selecting reporter constructs that are 5 expressed in the desired cell type, and by inserting the hybrid gene library into an appropriate expression vector (that is, into a vector that directs protein in the desired cell type) (see Example 4). Suitable expression vectors and reporter genes for a wide array of systems are well known in the art.

The novel transcriptional activators described herein are particularly useful 10 for introduction into cells to stimulate transcription therein since these new activators, even when over-expressed, do not interfere with transcriptional activation by classical activators such as the acidic activators. These activators are therefore highly useful for all applications involving controlled gene activation.

The novel transcriptional activators of the present invention can be delivered 15 to cells by any of a variety of available techniques. For example, where the DNA binding moiety consists of a polypeptide, the transcriptional activator can be delivered to the cells in the form of a gene linked to a promoter that is expressed in the cells. Techniques for gene delivery to cells are well known in the art and include transformation, transfection, electroporation, infection, etc. Where the DNA 20 binding moiety does not constitute a polypeptide, or where the transcriptional activator is delivered to cells as an intact protein, the transcriptional activator can be delivered by means of known drug delivery systems such as lipid micelles, or any other available technique.

Particularly preferred uses of the transcriptional activators of the present 25 invention are in gene therapy. Specifically, many diseases are known or proposed either to be caused by reduced expression of a particular gene, or to be alleviated by increased expression of a particular gene. For example, diabetes results from reduced expression of insulin, and many cancers are caused by mutation of tumor-suppressor genes. Many other diseases (including, e.g., cystic fibrosis) can also be 30 treated by gene therapy. The present transcriptional activators can be employed to treat such diseases. Specifically, a transcriptionally activating peptide of the present

invention is linked to a DNA binding domain that recognizes a site appropriately located relative to the relevant gene so that the activator is effective when bound to the site. The activator is then delivered to appropriate cells by any available technique and is allowed to stimulate gene transcription. If desired, the activator can

5 be provided to the cell as a gene under the control of a regulated promoter, so that expression of the activator in the cells can be controlled by exposure to an inducing agent. Such inducible promoters are well known in many systems. For example, useful human promoters include the glucocorticoid promoter, the NF κ B promoter, the tetracycline promoter, or any other agent-responsive promoter. In one

10 embodiment, the activator binding site is linked to a normal copy of a gene that is mutated in the cell. For example, where disruption of a gene results in a disease phenotype that is alleviated by introduction of a normal copy of the gene into the cell, the normal copy of the gene can be linked to a binding site for one of our activators and introduced into the cell along with the activator.

15 The present invention therefore encompasses methods of activating transcription by providing a novel transcriptional activator to a cell and recruiting that activator to a promoter at which it activates transcription. In preferred embodiments of the invention, the activator is recruited to the DNA by virtue of its being covalently attached to a DNA binding domain. However, it is also possible

20 that mere expression of the activating peptides of the present invention in a target cell will activate transcription if the activating peptides themselves have the ability to interact both with a target in the transcription machinery and with another factor that recruits them to the DNA.

By providing novel transcriptional activators, the present invention also

25 provides methods of identifying factors that interact with these activators, for example by standard biochemical, immunological, and/or genetic methods, or by the improved methods described herein. Once an interaction partner (or partners) is identified, that partner can be used in similar interaction-type assays to identify additional novel transcriptional activators of the type described herein.

System for Identifying Protein-Protein Interactions

In addition to providing novel transcriptional activators and associated methods of production and use, the present invention provides improved transcriptional activation systems for identifying and analyzing protein-protein interactions. As mentioned above, transcriptional activation systems have for several years been recognized as useful means for identifying interacting protein pairs. Such systems are often referred to as "two-hybrid" (see, for example Fields et al., *Nature* 340:245, 1989) or "interaction trap" (see, for example, Gyuris et al., *Cell* 75:791, 1993) assays.

The basic idea of these protein-protein interaction systems is exemplified in Figure 7. A first protein or protein portion (protein A in Figure 7), that does not itself stimulate transcription, is fused to a known DNA binding domain and the fusion product is expressed in a cell. The cell also contains a reporter construct in which the recognition site for the DNA biding domain is linked to a detectable reporter gene. A second fusion protein, in which a protein or protein portion that interacts with protein A (protein B in Figure 7) is fused to a transcriptional activation domain, is also expressed in the cell. Interaction between protein A and protein B recruits the transcriptional activation domain to the DNA so that transcription of the reporter construct is induced.

These protein-protein interaction systems have been used to identify interaction partners for known proteins by fusing the known protein to either the DNA binding domain or the transcriptional activation domain and introducing the resulting fusion into cells along with a library fused to the other of the activation domain and the DNA binding domain. Typically, such assays are performed in yeast systems, with either β -galactosidase or a selectable marker (or both) as the reporter gene, but analogous systems have been developed in other cell types (see, for example, Vasavada et al., *Proc. Natl. Acad. Sci. USA* 88:10686, 1991; Fearon et al., *Proc. Natl. Acad. Sci. USA* 89:7958, 1992; Finkel et al., *J. Biol. Chem.* 268:5, 1993, each of which is incorporated herein by reference).

Many interacting protein pairs have been identified through the application of such systems (for reviews, see Fields et al., *Trends Genet.* 10:286, 1994; Allen et

al., *Trends Biol. Sci.* 20:511, 1995, each of which is incorporated herein by reference), and standardized protocols can be found in readily available textbooks (see, for example, Shirley et al., *Methods Cell Biol.* 49:401, 1995, incorporated herein by reference).

5 Despite the success that has been achieved with known protein-protein interaction systems that rely on transcriptional activation, important drawbacks of the systems have also been identified (for discussions of drawbacks in reviews, see Fields et al., *supra*; Allen et al., *supra*). False positives are common. Moreover, these systems typically cannot be used to identify the interaction targets of

10 transcriptional activators. Quite simply, if the activator is fused to the DNA binding moiety, the fusion activates transcription and the screen cannot be performed; if the activator is supplied as an activation domain, the assay typically still cannot identify interaction targets because the activator often cannot interact simultaneously with a DNA-bound version of its target and its target in the transcriptional machinery.

15 Thus, interaction of the activator with its DNA-bound target precludes recruitment of the transcriptional machinery.

20 The present invention provides improved transcriptional activation systems for identifying protein-protein interactions. Figure 8 presents one embodiment of an improved transcriptional activation of the present invention. The improvement depicted in Figure 8 is that Gal11 is employed as the activator in a standard interaction trap or di-hybrid fusion assay. Thus, the target protein depicted in Figure 8 is preferably not a transcriptional activator (or other component of the transcription machinery that, when recruited to DNA through linkage with a DNA binding domain, activates transcription).

25 In the system presented in Figure 8, the DNA binding domain can be any DNA binding moiety that recognizes a known DNA sequence, but preferably corresponds to or includes a DNA binding domain of a known protein, most preferably of a transcriptional regulator for review, see Nelson, *Curr. Op. Genet. Dev.* 5:180, 1995. The most preferred DNA binding domains for use in these assays are the Gal4 (at least 1-100) and LexA(1-202) DNA binding domains.

The reporter gene utilized in the system of Figure 8 can be any gene whose expression is readily detectable. In yeast systems, preferred reporters include the β -galactoside gene and selectable genes such as *HIS3*, *LEU2*, *URA3*, etc.; in human systems, the preferred reporter genes are those for SV40 large T antigen used in 5 CV-1 cells; Vasvada et al., *Proc. Natl. Acad. Sci. USA* 88:10686, 1991), CD4, cell-surface molecules that can be selected in a cell sorter, or drug-selectable markers (Fearon et al., *Proc. Natl. Acad. Sci. USA* 89:7958, 1992).

Use of Gal11 as the activation domain in protein-protein interaction systems has many advantages over existing approaches. First of all, Gal11 is the most 10 powerful known yeast activation domain (Himmelfarb et al., *Cell* 43:1299, 1990, incorporated herein by reference). Thus, assays employing Gal11 are likely to be even more sensitive than are existing systems and therefore to be useful for detecting weaker protein-protein interactions than are currently observed.

Furthermore, Gal11 does not squelch activation by known acidic activators, 15 even when it is expressed at high levels (Barberis et al., *Cell* 81:359, 1995, incorporated herein by reference). Use of Gal11 in the transcriptional activation systems described herein therefore avoids toxicity problems often associated with over-expression of strong transcriptional activators.

Without wishing to be bound by any particular theory, we propose that Gal11 20 does not squelch transcriptional activation by acidic activators because it activates transcription through a different mechanism than that employed by the acidic activators. Specifically, we propose that Gal11 is part of the yeast RNA polymerase II holoenzyme and activates transcription when it is recruited to DNA simply because it, in turn, recruits the rest of the transcriptional machinery (see Barberis et 25 al., *supra*). The present invention therefore encompasses the finding that use of RNA polymerase II holoenzyme components as transcriptional activation domains improves protein-protein interaction systems that assay for transcriptional activation.

Any component of the RNA polymerase II holoenzyme, or any artificial sequence that interacts with the holoenzyme, can be tested for its ability to be used 30 as the transcriptional activation domain in the improved protein-protein interaction systems of the present invention depicted in Figure 8. Recognizing that the literature

includes differing descriptions of the RNA polymerase II holoenzyme, we define a "holoenzyme component" for the present purposes as any factor associated with the holoenzyme in a holoenzyme preparation that, when used in an *in vitro* transcription assay, responds to addition of purified transcriptional activator (e.g. Gal4; see, for 5 example, Koleske et al. *Nature*, 368:466, 1994).

As mentioned above, one of the advantages of using Gal11 or another component of the RNA polymerase II holoenzyme as the transcriptional activation domain in a protein-protein interaction assay of the type described herein is that such factors do not squelch other known activators. In light of this teaching, one of 10 ordinary skill in the art will recognize that other transcriptional activators that do not squelch acidic activators, even though the other activators are not components of the RNA polymerase II holoenzyme, are useful in the improved transcriptional activation systems of the present invention. For example, the novel transcriptional activators described above can be employed in the transcriptional activation systems described 15 herein.

Figure 9 presents another embodiment of an improved transcriptional activation system of the present invention, which embodiment we term the "three-component" system. In the three-component system of the present invention, a test protein is fused either to a non-Gal4 DNA binding domain or to Gal4(1-100), and an 20 interaction target (e.g., a library) is fused to the other. Both fusion constructs are introduced into yeast cells carrying a mutant Gal11 that has gained the ability to interact with Gal4(1-100), and also carrying a reporter gene linked to the DNA binding site for the non-Gal4 DNA binding domain. Preferred embodiments employ the Gal11P allele (Himmelfarb et al., *Cell* 63:1299, 1990).

25 The Gal11P allele was first identified as a mutation that potentiated the activity of weak Gal4 derivatives (Himmelfarb et al., *Cell* 63:1209, 1990). We have since found that Gal11P is a gain-of-function mutation that confers onto Gal11 the ability to interact with the Gal4 dimerization domain found in Gal4(1-100) (Barberis et al., *Cell* 81, 359, 1995). Thus, in preferred embodiments of the three-component 30 system of the present invention, interaction between the selected protein and its target recruits Gal4(1-100) to the DNA. Interaction between Gal11P and Gal4(1-100)

then recruits the RNA polymerase II holoenzyme, thereby stimulating gene transcription (see Example 5). The affinity of the selected protein for its target correlates at least roughly with the observed level of transcriptional activation (see Example 5; see also Estojak et al., *Mol. Cell. Biol.* 15:5820, 1995, Yibing Wu, 5 Ph.D. dissertation, Harvard University, 1996, incorporated herein by reference).

The three-component system of the present invention does not require use of the Gal11P allele *per se*. For example, the original Gal11P mutant bore an Ile residue at position 342 (Himmelfarb et al., *Cell* 63:1299, 1990). Subsequent randomization of codon 342 revealed that substitution with other hydrophobic 10 residues (e.g., Leu or Val, to a lesser extent Met or Thr) yields the Gal11P phenotype to different extents (Barberis et al., *Cell* 81:359, 1995). Any of these Gal11 derivatives is useful in the practice of the present invention. Furthermore, the general principle observed is readily generalizable. That is, the present invention teaches an improved protein-protein interaction system employing an RNA 15 polymerase II holoenzyme component gain-of-function mutation where the gain of function comprises an ability to interact with a component to which other entities can be fused for the performance of a three-component screen as described herein. Any other appropriate holoenzyme component mutant could readily be employed in the practice of the present invention.

20 The three-component system of the present invention has many advantages over existing protein-protein interaction systems. The primary advantage is that use of the mutant holoenzyme component (e.g., Gal11P) system provides a straightforward control that can be used to distinguish "true" positives, that rely on recruitment of the transcription machinery to the promoter, from "false" positives 25 produced sporadically by the system. For example, in a screen in which a selected protein (e.g., a transcriptional activator) is linked to Gal4(1-100) and a library is linked to the DNA binding moiety, "positive" library clones (i.e., those that encode a true interaction partner to the selected protein) are identified as those that result in transcriptional activation in a Gal11P cell but not in a Gal11 cell. Better yet, the 30 screen is performed in a Gal11 cell that also contains the Gal11P gene under the control of a regulatable promoter. The screen is performed under conditions in

which the Gal11P gene is expressed (since Gal11P is a dominant mutation, this expression effectively converts the cell to a Gal11P cell), and then the same colonies are tested under conditions in which the Gal11P gene is not expressed. This strategy avoids the complication of having to isolate plasmids from individual Gal11P colonies transform them into Gal11 cells and re-test the new transformants.

Also, because the transcriptional activation in this system is via the "Gal11" mechanism, over-expression of the selected protein-Gal4(1-100) fusion will not squelch endogenous activators. Furthermore, in preferred embodiments of this three-component system, where the selected protein fused to Gal4(1-100) is a transcriptional activator, the system offers an additional built-in advantage. Specifically, the integrity of the Gal4(1-100) fusion can readily be tested by providing the cell with a second reporter construct, this one including Gal4 DNA binding sites, and detecting activation of that promoter by the fusion. One of ordinary skill in the art will readily recognize that this integrity control may be performed simultaneously with or separately from any protein-protein interaction screen. That is, the second reporter can be introduced into a cell with just the Gal4(1-100) fusion, or with any or all of the other constructs used in the full screen.

Applications of the improved transcriptional activation systems described herein are, of course, not limited to the identification of new protein-protein interactions. As is known for the standard di-hybrid and interaction-trap systems, such assays can usefully be employed to test the existence or dissect the specifics of a protein-protein interaction (see, for example, Fields et al., *Trends Genet.* 10:286, 1994; Allen et al., *Trends Bioch. Sci.* 20:511, 1995). For example, the significance of mutations, deletions, or insertions in different regions of the interacting components can be assayed by studying their effects on transcriptional activation in these systems. Techniques for producing such mutations, deletions, and insertions are well known in the art. The advantages described herein of being able to examine the significance of effects, for example by comparing results in Gal11P and Gal11 cells, are equally applicable to these types of assays.

Other Embodiments

One of ordinary skill in the art will readily recognize that the foregoing represents merely a detailed description of certain preferred embodiments of the present invention. Various modifications and alterations of the compositions and 5 methods described above can readily be achieved using expertise available in the art, and are within the scope of the following claims.

For example, as mentioned above, all of the assays described herein can be performed in any of a variety of cell types. Yeast cells are often selected as the most convenient for experimental manipulation, but even there, the variety of yeast 10 strains that are available affords a wide range of opportunity for the practice of the present invention.

In some instances, it may be desirable to perform the assays of the present invention in cells whose capacity for transcriptional activation has been altered. For example, we have identified various dominant mutations in the yeast TBP protein 15 that enhance the transcriptional activation potential of various yeast activators (see Example 6). Specifically, the N69R and V71R mutations of yeast TBP, when expressed from an ARS-CEN plasmid in otherwise wild type yeast, increase the observed transcriptional activity of G4RII' derivatives by 2-3 fold, and that of a Gal4-Gal11 fusion (form a site 1200 basepairs upstream of the transcription start) 12 fold. Use of such mutant TBPs in the assays described above may make the system 20 more sensitive.

Examples

25 **EXAMPLE 1: Identification and Characterization of Novel Transcriptional Activators**

Materials and Methods

MEDIA, YEAST STRAINS, AND REPORTER/PLASMIDS: Rich (YPD) and synthetic complete (SC) yeast media were prepared as described (Rose et al., *Methods in Yeast Genetics*, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1990, incorporated herein by reference). Yeast strain JPY9 was described in Wu et al., *EMBO J.* 1996.

The genotype of JPY9 is *MATα, ura3-52, trp1Δ63, leu2Δ1, his3Δ200, lys2Δ385, gal4Δ11, gal80*. Yeast reporter plasmids pRY131Δ2μ, pRJR227, and pJP169 contain the reporter gene, *lacZ*, and various upstream activating sites: UASg of GAL-lacZ, five consensus 17mer GAL4 binding sites, and two LexA binding sites, respectively. These upstream activating sites are all 191 bp away from the TATA box (Yocum et al., *Mol. Cell. Biol.* 4:1985, 1984; Carey et al., *Science* 247:710, 1990). Reporter plasmids were integrated at the URA3 locus of yeast after *Apal* digestion.

LIBRARY CONSTRUCTION: The following oligonucleotides were synthesized:
10 oligo1 has 30 nucleotides paring the upstream of coding sequence of GAL4(1-100) in plasmid pRJR217 (Wu et al., *EMBO J.*, 1996); oligo2 contains 30 nucleotides paring downstream of GAL4(1-100) coding sequence, a stop codon, 24 random nucleotides, and 18 nucleotides paring the C-terminus of GAL4(1-100) coding sequence; oligo3 contains 30 bp paring the downstream of GAL4(1-100) coding sequence, a stop codon, 18 random nucleotides, and 18 nucleotides paring the C-terminus of GAL4(1-100+840-850) coding sequence. DNA fragments encoding GAL4(1-100)+X8 or GAL4(1-100+840-850)+X6 were then generated by PCR using primer pairs oligo1-2 and oligo1-3, respectively, and using plasmid DNA RJR217 encoding GAL4(100), and pRJR206 encoding GAL4(1-100+840-850), respectively, as template. These
20 PCR fragments were co-transformed into *S.cerevisiae* strain JPY9::RJR227 using LiOAc method (Rose et al. *supra* 1990) along with a yeast expression vector, pRJR217, that was linearized with *NcoI* and *Sall*. The PCR fragments were integrated into the vector by homologous recombination (Lehming et al., *supra* 1995), yielding a library of yeast colonies.

25 ACTIVATION ASSAY: The yeast colonies, 2-3 days after transformation, were subject to X-gal filter assay (Rose et al., *supra* 1990). Blue colonies were selected, plasmids were rescued from these colonies and re-transformed into yeast strain JPY9::RJR227 and JPY9::RY131Δ2μ. β-galactosidase activities were then determined by X-gal filter assay and ONPG liquid assay (Rose et al., *supra* 1990).

30 SQUELCHING ASSAY: The plasmids encoding the activating peptides were transformed into the yeast strain JPY9::JP169 along with a plasmid encoding lexA(1-

87)-GAL4(74-881), or lexA(1-87)-GAL11(141-1081). Both activating peptides and lexA-GAL4 or lexA-GAL11 are in the plasmids, driven by the actin promoter. Both plasmids have the Ars-Cen replicating origin. Because the activating peptide gene and the lexA-fusion genes are under the control of the same promoter, they should 5 be produced at the same level in yeast cells. The transformed cells were assayed for β -gal activity and compared with the cells that were transformed with lexA-GAL4 or lexA-GAL11 alone.

SEQUENCING: All plasmids encoding the activating peptides were sequenced using sequenase v2.0 kit from Amersham/USB.

10 ACTIVATION IN MAMMALIAN SYSTEM: The DNA encoding the yeast activating peptides was amplified by PCR and cloned into an mammalian expression vector, pcDNA3 (from Invitrogen). The resulting plasmids were co-transfected into HeLa cells along with a reporter plasmid pG5EC which encodes a chloroamphenicol acetyl transferase (CAT) gene driven by the minimal adenovirus *E1b* promoter bearing five 15 upstream consensus 17 mers of GAL4 binding sites. The CAT activities were determined using [14 C] chloroamphenicol as substrate (Sambrook et al. Molecular Cloning: a Laboratory Manual, 2d Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

20

Results

We constructed expression libraries that would produce a Gal4 DNA binding domain (either 1-100 or 100+840-850) fused to short, randomized peptides (6 or 8 amino acid residues in length). We transformed these libraries into a yeast strain 25 containing a reporter plasmid that included Gal4 DNA binding sites. One reporter plasmid (pRJR227) contained five Gal4 17-mers upstream of the β -galactosidase gene; another (p4131 Δ 2 μ) contained a natural UAS_G upstream of the same gene. We selected blue colonies by X-gal filter assay, recovered plasmids from the yeast cells in these blue colonies, and re-transformed and re-screened these positive 30 plasmids. From approximately 200,000 colonies screened, we obtained approximately 200 activators. Transcriptional activation by each of these activators

was dependent on the presence of Gal4 binding sites in the reporter construct, indicating that activation is specific. The activation potential varied among the activators (see Table 1); several (~ 5%) activated better than did full-length Gal4.

We determined the nucleotide sequence of the inserts in our positive clones, and thereby determined the amino acid sequence of the transcriptional activators (see Table 1). Although no obvious consensus sequence emerged, we found that our peptide activation domains contained primarily hydrophobic and acidic residues. No basic residues were observed, except in one weak activator. Each of our peptide sequences was new—that is, no peptide correspond to a known sequence in the SwissProt database.

TABLE 1
Activators from Random Library GAL 1-100+840-850+X6

Plasmid	Sequence	β -gal Activity (5X17 mers)		Net Charge
		Plate Assay	Liquid Assay	
RJR191	GAL4 1-881 (Full length)	+++	2350	
RJR182	GAL4 1-100+840-881	++	1739	
RJR217	GAL4 1-100	-	3	
RJR206	GAL4 1-100+840-850 (840 <u>WTDQTA</u> YNAFG 850)	±	41	
LS1	CCC CTC TTN NCN NCC CTC	++		
LS2	ATT CCG CCA CCG TAT TTC I P P P Y F	++		0
LS3	CTG CCC GGG TGT TTC TTC L P G C F F	++		0
LS4	CAG CTC CCC CCC TGG TTA Q L P P W L	++	1882	0
LS5	TAC TGG CCC TCC CCC TTC Y W P S P F	++		0

LS6	GAG TTC CCC TAT GAC TTG E F P Y D L	+		-2
LS7	ACC GCC GAA TTC CCC CTC T A E F P L	++		-1
LS8	CAA TTT CTA GAC GCA CTT Q F L D A L	+	1174	-1
LS9	ACA TTC CCT GAC CCC TTC T F P D P F	+		-1
5 LS10	ATC GGC CCA NCN CTT TTC	++		
LS11	TTG GAT TTT TCC TAC GTC L D F S Y V	+++	2196	-1
LS12	CCC CCA CCA CCC TGG CCC P P P P W P	+++	2109	0
LS13	CTC TTT GAA TGA GGA ACC L F E *	+		-1
LS14	CTG CTC GAC ATA CCT TTC L L D T O F	++		-1
10 LS15	CTC CCC GAC GCC TTT CTC L P D A F L	++		-1
LS16	CTC TTC CCC GAC CTC AAC L F P D L N	++		-1
LS17	TCT TGG TTT GAT GTC GAA S W F D V E	++	1961	-2
LS18	CTT GAA CCT CCG CCC TGG L E P P P W	++		-1
LS19	CAG CTA CCT GAT CTG TTC Q L P D L F	+++	1727	-1
15 LS20	CCT CTC CCA GAC CTC TTC P L P D L F	+++	2215	-1
LS21	TTC GAA TTC GAT GAT ATC F E F D D I	++	9814	-3
LS22	ACC TTT TTC GAT ACC CCC T F F D T P	+		-1
LS24	CAA TAC GAT CTA TTC GAT Q Y D L F D	++	1153	-2

LS25	CTA CCG GAC TTA ATT CTC L P D L I L	++	1229	-1	
LS26	CCC CCC CTG GAT CCA TGG P P L D P W	++		-1	
LS27	CAA TAC GAT CTA TTC GAT Q Y D L F D	++		-2	
LS28	ACC TTG TGA CGC CAG AGC T L *	++		0	
5	LS30	CTA CCA GAC TTC GAT CCA L P D F D P	+	886	-2
	LS35	CTA ATC CCA TAC TCC CTG L F P Y S L	++	1825	0
	LS40	TTT CCT GAC CTC TTC CCC F P D L F P	++		-1
	LS41	CCT AAC CCC TTC CCA CTG P N P F P L	++		0
	LS42	TTC TAG AAC ACA CCC CCG F *	±		0
10	LS43	CCC CCC CCC CAA TAT TTC P P P Q Y F	+		0
	LS44	GAG GAC ACC CCC CCC TGG E D T P P W	±	552	-2
	LS46	TTC CCC CCC CCC CCA TTC F P P P P F	++		0
	LS51	TTC CCC CCA TTC AAC CAA F P P F N Q	+	950	0
	LS52	CCC CTG TTC TGA CTC GGA P L F *	+		0
15	LS53	ACC GGT CCA CCA GAG CTA T G P P E L	+		-1
	LS60	CTA ATC CCA TAC TCC CTG L I P Y S L	+		0
	LS61	ACC TTC CCT TAC TCA CTG T F P Y S L	++		0
	LS62	GGC AGC TTC GAA CTC CTC G S F E L L	+		-1

	LS63	CTG GAA TAC CCC ACC ACC L E Y P T T	+		-1
	LS64	AAT TTT GAT GAC CTA CTC N F D D L L	+++	1905	-2
	LS66	CTG GAC GTA TTT TCA CAC L D V F S H	++		-1
	LS101	CAG CTA CCT GAT CTG TTC Q L P D L F	++		-1
5	LS102	CAC CCC CCC CCT CCC ATT H P P P P I	++	1158	0
	LS104	CCC CTG TTC TGA CTC GGA P L F *	++		0
	LS105	CTG CCC GGG TGT TTC TTC L P G C F F	++	2403	0
	LS106	CAA TAC GAT CTA TTC GAT Q Y D L F D	+	1385	-1
	LS107	GCT CTC CCG CCG TAC CTC A L P P Y L	+		0
10	LS108	TTC CTC CCC TCC CTT CCC F L P S L P	++		0
	LS110	ATC CCT CTC CTC TGT CTC I P L L C L	±	122	0
	LS111	ATG CTC CCT CCC TAC ATC M L P P Y I	++		0
	LS114	CCC CCC TAC ATA TGG CCA P P Y I W P	++		0
	LS115	GCG CTA TGG TAG CTA CCC A L W *	++		0
15	LS118	GAC CTC AAT ATT TTC TAG D L N I F *	++		-1
	LS119	CTA CCC ATG ACN CCG TTC L P M T P F	+		0
	LS120	TAC CCC CCG CCG CCC TTT Y P P P P F	+	1443	0
	LS121	NNN CCC GTA GNN CNC TGG	++		

LS123	CCC CTT CCN CCT TTT CTT P L P P F L	+++	1892	0
LS125	CTC CCC ACC ATG CCC CTC L P T M P L	+		0
LS126	CTC TTC CTA CCA CCC ACC L F L P P T	+		0
LS129	ACC GCC GAA TTC CCC CTC T A E F P L	+		-1
5 LS130	ACC GAT TTC CTT CTG CTG T D F L L L	++		-1
LS131	GGA GAA TAT TTC CCC TTC G E Y F P F	++		0
LS132	TTT ATA GAT CCC CCT CTC F I D P P L	++		-1
LS133	CTA ATC CCA TAC TCC CTG L I P Y S L	++		0
LS134	CAA TAC GAT CTA TTC GAT Q Y D L F D	++		-2
10 LS135	TTA CCT CCC CCC TGG CTT L P P P W L	+++	3121	0
LS136	CTC TGG CCA CCT GCC GTA V W P P A V	+++	1829	0
LS140	CCA ACA AAC TTC TAC TGA P T N F Y *	+		0
LS142	CTA ATC CCA TAC TTC CTG L I P Y F L	+		0
LS147	ATC TGC GAG AGT TTC TTT I C E S F F	++		-1
15 LS148	GCG GAC CCG TGG CTA CTC A D P W L L	++		-1
LS149	GCG CAG TAC CCT TTC TTC A Q Y P F F	++		0
LS150	CCT CCG TCA TTC TTC GGC P P S F F G	++		0
LS151	CTT TCC AGC CTT CCC TTC P S S L P F	++		0

LS152	GAC CCA CCA TGG TAC CTT D P P W Y L	+	1783	-1
LS153	CTC TAC TAA TAA TAA GCA L Y *	+	1262	0
LS155	CCT ATC CCC GGT TTC ACT P I P G F T	+		0
LS158	TTT GAC CCC TTG GGC ATC F D P F G I	+	1856	-1
5 LS160	CCC CCC AGT GTG AAC CTC P P S V H L	+++	2891	0
LS161	CCA GAC AAC GTC CTA CCG P D N V L P	++		-1
Activators from Random Library GAL4 1-100+X8				
Plasmid	Sequence	Net Charge	β -gal Activity (in YAG ₆)	
			X-gal	ONPG
RJR191	GAL4 (1-881, Full length)		+++	2804
10 RJR217	GAL4(1-100) (89 <u>K</u> ALLTGLFVQ <u>D</u> 100)		-	3
LS201	TAC CTT TTA CCA ACC TGT ATA CCT Y L L P T C I P	0	++++	4395
LS202	CTA CAA GTC CAC AAC AGC AGA TAG L Q V H N S T	0	++	1655
LS203	GTT CTT GAC TTC ACC CCT TTC CTC V L D F T P F L	-1	++	1128
LS205	CCC CTT ACC TAC CCC CTC GCC GGA P L T Y P L A G	0	+	325
15 LS206	CTC CTC GCC TTT TAC GAG ATA CCG L L A F Y E I P	-1	+++	1423
LS207	CCC CCT GAC ACC TAC ATC TTC TTA P P D T Y I F F	-1	+	
LS208	CAA CTC AAC TAC CCA CTC GCC ATA Q L N Y P L A I	0	+	173

5	LS209	CTC GTA CTA CCC CAG CCG CAA CTC L V L P Q P Q L	0	+	
	LS212	CCT TGG TAC CCT ACG CCG TAT CTG P W Y P T P Y L	0	++	811
	LS215	TGG CTC CGA TCG TTC AGC GTT CCC W L R S F S V P	+1	±	187
	LS217	CTT GAA CCA TCA CTA TAT ATG ATA L E P S L Y M I	0	+	
	LS218	TGC ATC TTG TCC CAC CAC GCT CCT C I L S H H A P	0	±	
	LS220	GAC CTC ACA TGC TGT TTT TGC CTC D L T C C F C L	-1	+	198
	LS221	CCG TTT ATT GGC GGC CCT TAC GCA P F I G G P Y A	0	+	
	LS223	TAC CTA CTA CCT TTC CTT CCG TAC Y L L P F L P Y	0	+++	2366
	LS224	TAC CCC TGG TTT CCA GTC CCC TTA Y P W F P V P F	0	±	
	LS225	TAT TTA CTA CCT CTC CTC TCC ACT Y F L P L L S T	0	+++	2714
10	LS226	CTC TCC ATT CAA CCC TAT TTT TTT L S I Q P Y F F	0	±	
	LS228	GCC CTA TTC TAC CTC CTC TAA AAG A L F Y L L *	0	+	419
	LS230	CCN TGG CCC TAC TAT TTN CCG ATC P W P Y Y F P I	0	+	
	LS231	CCG ATT TGG CAA TAT ACC ATT TTC P I W Q Y T I F	0	+	
	LS232	TTA TCC CCC ACC TTT TGG GCA TTC F S P T F W A F	0	++	
	LS233	GAC CCC CCC TAC GCC TAT ACT CTG D P P Y A Y T L	-1	+	126
15	LS235	CCT GCA CTC CTG TTT CCA TTC ATC P A L L F P F I	0	+	763
	LS236	TTC ACC TAC GCT CTC CCC TTC CCC F T Y A L P F P	0	+	390

LS239	CTC TTA CCA CTG CCT CTC TTC CTC L F P L P L F L	0	±	
LS240	CTA TTC CCC TGG ACA TAC CAA CTT L F P W T Y Q L	0	+	
LS241	CTT ATT ATG AAC TGG CCT ACA TAT L T M N W P T Y	0	++	
LS243	TAT ATT TTC NCG CTG AGC TTA TCA Y I F ? L S F S			
5 LS244	CTA ACA CCC CTC CCC TCA TGG CTA L T P L P S W L	0	+	

We investigated the importance of the hydrophobic and acidic residues in our peptide activation domains by performing site-directed mutagenesis on selected activators. In particular, we converted the I residue of activator LS201 to a R, and 10 found that the formerly strong activator was converted to a weak one. This finding indicates that positive charge does not correlate with activation potential in our activators.

We also tested the importance of peptide sequence by scrambling the residues of the LS201 activator. As shown in Figure 1, such scrambling reduces activation 15 potential about 44-260 fold.

We also performed "squelching" assays (Gill et al., *Nature* 334:721, 1988) with our activators. Specifically, we tested whether over expression of our activators affected transcriptional activation directed by LexA-fused activators from a template containing 2 LexA binding sites 141 base pairs upstream of a *Gall-LacZ* 20 gene fusion (pJP168). Each of the activators tested squelched activation by other of our activators; however, none of our activators squelched activation by either lexA-Gal4 or lexA-Gal11 (see Table 3). This finding suggests that our new transcriptional activators act through a target distinct from that contacted by either Gal4 or Gal11. Without wishing to be bound by any particular theory, we propose that our novel 25 transcriptional activators stimulate transcription by contacting surfaces in the RNA polymerase II holoenzyme that are not contacted by other, known transcriptional activators. Thus, these novel transcriptional activators can be introduced into cells

without deleterious effects on natural transcription activation mechanisms at work in those cells.

TABLE 2				
Activating Peptides do not Squelch Activation by LexA-Gal4 or LexA-Gal11				
Novel Activator	LexA-Gal4 Units of β -Galactosidase Activity	% Activation	LexA-Gal11 Units of β -Galactosidase Activity	% Activation
none	3216 \pm 241	100	3450 \pm 200	100
Gal4	520 \pm 245	16	2504 \pm 410	73
LS64	3306 \pm 758	103	4153 \pm 515	120
LS110	2785 \pm 672	87	3518 \pm 622	102
LS160	3383 \pm 782	105	3833 \pm 842	111
LS201	2842 \pm 308	88	4288 \pm 621	124

We investigated the role played by the DNA-binding domain residue immediately adjacent the peptide in our novel activators. Specifically, we deleted that residue, an aspartic acid, and tested the ability of the deletion derivatives to activate transcription on a template containing 5 Gal4 17mers upstream of a *Gal4-LacZ* gene fusion (pRJR227). We found that the alanine does participate in transcriptional activation (Table 3).

20

25

TABLE 3	
Role of D ¹⁰⁰ in Activation by Gal4 (1-100)-Peptide Activators	
Activator	β -galactosidase Activity in JPYP:RJR227
Gal4	2958
Gal4(1-100)	3
LS201	5288
LS201 Δ D ¹⁰⁰	207

LS164	1716
LS164ΔD ¹⁰⁰	84

**EXAMPLE 2: Analysis of DNA Binding Domain Residues that Contribute to
5 Transcriptional Activation; Identification of Additional Novel Transcriptional
Activators**

Materials and Methods

ANALYSIS OF CONTRIBUTING DNA BINDING RESIDUES: Activator LS201, described above in Example 1, was mutagenized according to standard techniques to 10 delete or substitute one or more of Gal4 DNA binding residues 96-100. Transcriptional activation by the resulting proteins was assayed on the pRJR227, as described above.

LINKAGE OF ACTIVATOR PEPTIDE TO PHO4 DNA BINDING DOMAIN: An activating peptide consisting of activator LS201 and Gal4 DNA binding domain 15 residues 96-100 was cloned onto the Pho4 DNA binding domain (residues 153-312, corresponding to Pho4Δ2) by PCR. The resulting construct was introduced into yeast cells and its activating capability was determined by assaying acid phosphatase activity in those cells, and comparing it to cells into which either full-length Pho4 or Pho4Δ2 was introduced. All methods were as described in Gaudreau et al., *Cell* 20 89:55, 1997 and Svaren et al., *EMBO J.* 13:4856, 1994).

Results

Gal4 DNA binding domain residues 96-100 were mutagenized in the context of a transcriptional activator comprising peptide LS201, and activation potential of 25 the mutants was assayed on a template in which five consensus Gal4 17mers were positioned upstream of a *GAL1-LacZ* reporter gene. Gene expression was detected by analysis of β -galactosidase activity. The results are presented in Figure 2. As can be seen, deletion of any one of Gal4 residues 96-100 reduced activation 10-2000 fold; substitution of either Phe97 or Val98 with Ala also significantly decreased 30 activation. By contrast, substitution of either Glu99 or Asp100 with Ala had little or

no effect on activation. Production of each of the mutant protein was confirmed by gel shift from whole cell extracts (data not shown).

To analyze the role of DNA binding residues further, we asked whether a peptide consisting of activator LS201 and Gal4 residues 96-100 could activate

5 transcription when linked to a different DNA binding domain. Specifically, we linked this peptide to the Pho4 DNA binding domain. We assayed the transcriptional activation capability of our new fusion protein by detecting its ability to stimulate expression of the *PHO5* gene, which encodes an acid phosphatase whose enzymatic activity can be analyzed according to known techniques (see Svaren et al.,
10 *EMBO J.* 13:4856, 1994). As shown in Figure 3, we found that the hybrid activator stimulated transcription as effectively as did full-length Pho4. We note that the fold activation shown in Figure 3 is misleadingly low due to unrelated acid phosphatase activity in yeast cells that contributes to a high background (e.g., that results in 30 units of activity when no functional activator is provided; see line re Pho4Δ2).

15

EXAMPLE 3: *In Vitro* Activation by Inventive Transcriptional Activators

IN VITRO TRANSCRIPTION WITH YEAST NUCLEAR EXTRACT: *In vitro* transcription with a yeast nuclear extract was performed as described by Wu et al., *EMBO J.* 3951, 1996. Specifically, yeast nuclear extract was prepared as described
20 (Ponticelli et al., *Mol. Cell. Biol.* 10:2832, 1990; Ohashi et al., *Mol. Cell. Biol.* 14:2731, 1994). Transcription reactions (25 μ l) contained 10 mM HEPES, pH 7.5, 10 mM MgSO₄, 5 mM EDTA, 10% glycerol, 2.5 mM dithiothreitol, 100 mM potassium glutamate, 10 mM magnesium acetate, 2% polyvinyl alcohol, 8 mM phosphoenolpyruvate, 0.62nM pG₂E4, 5.5 nM pGEM3Z (Promega), and 3 μ l yeast
25 nuclear extract, (60 mg/ml). Reactions were incubated with Gal4 protein form 10 min at 25 °C. Nucleoside triphosphates were then added to a final concentration of 1 mM and the reactions were allowed to proceed for an additional 60 min at 25 °C. Primer extension was performed using an oligonucleotide to the E4 coding sequence as described (Lillie et al., *Cell*, 46:1043, 1986; Lin et al., *Cell*, 5:659, 1988).

30 *IN VITRO* TRANSCRIPTION WITH YEAST HOLOENZYME: Yeast holoenzyme was prepared as described in Koleske et al., *Nature* 368:466, 1994 and depicted in

Figure 4. Recombinant TBP and TFIIE were added to the holoenzyme fraction to reconstitute transcriptional activity. Otherwise, reactions were as described above for yeast nuclear extract transcription.

5 *Results*

Activator LS201, fused to the Gal4 DNA binding domain, was assayed for its ability to activate transcription. Figure 5 shows transcriptional activation by the Gal4-LS201 protein on a template containing five consensus Gal4 17mers. The activator stimulated transcription when added in 1, 5, and 30 ng amounts; above 10 those levels (100 ng), the activator squelched transcription. Similar results were obtained when the transcription was mediated by the yeast holoenzyme rather than a nuclear extract (see Figure 6). In these reactions, Gal4-LS201 activated transcription to levels comparable to those observed with Gal4-VP16. Squelching was again observed at high concentrations of Gal4-LS201.

15

EXAMPLE 4: Identification of Novel Transcriptional Activators in Mammalian System

Generally

We will by DNA synthesis extend a gene encoding the DNA binding domain 20 of GAL4 (residues 1-100). The nucleotides will be added without regard to sequence at first, although as results indicate we may bias these sequences (see below). DNA molecules encoding the DNA binding domain fused to additional peptide sequences, attached to a strong promoter, will be transfected into mammalian cells bearing a fluorescent reporter. For example, a fusion gene encoding green 25 fluorescent protein will be put under control of the minimal *E1b* promoter bearing upstream GAL4 binding sites. Such a reporter will be expressed when bound by an activator. A fluorescence activated cell sorting (FACS) machine will be used to isolate cells expressing the reporter at high levels. We will use PCR to recover the sequence of the new activators. We predict that at least some of these new 30 activators will work at very high efficiencies and yet will have no inhibitory effects on cells even when expressed at high concentrations (see below). We might then

take our best activators and subject them to further rounds of peptide addition and screening to find even better activators. We describe the experiment in more details next.

5 *Construction of Stable Reporter Cell Lines*

We will use a vector encoding enhanced GFP (EGFP)-neomycin fusion protein as a reporter. EGFP fluoresces 35-fold more intensely and is also more soluble than wild type GFP. Expression of EGFP will allow us to use a FACS machine to separate out cells interest of, whereas the neomycin resistance gene will 10 allow us to obtain our targets as stable cell lines. this double reporter can help us eliminate false positive clones while screening the random library.

The reporter plasmid will be constructed by PCR and restriction enzyme digestion-ligation. Starting from an expression vector, pEGFP-C1 (available from CLONTECH) which contains a selective marker, hygromycin resistance gene, we 15 will fuse a neomycin resistant gene in frame to the C-terminus of EGFP. The DNA cassette, containing five 17 mers of GAL4 high affinity binding sites upstream of the minimal adenovirus E1bTATA promoter, will replace the CMV promoter. The resulting reporter plasmid, pGSEFO, will be transfected into a mammalian cell line (e.g. HeLa, CHO), and hygromycin resistant cells will be selected and cloned to 20 generate the stable reporter cell lines. The reporter cells can be tested by PCR for plasmid integration and by transfection of the activator GAL4-VP16 plasmid for the reporter expression. The reporter cell lines will be maintained in hygromycin medium and should have no or little expression of EGFP and neomycin in the absence of activators.

25

Construction of Random Libraries

We will start by adding 8 random residues to GAL4(1-100) DNA binding domain. We will, if needed, extend the random peptide to isolate more potent activators (see below). An oligonucleotide will be synthesized to contain the 30 following: a restriction site, a stop codon (TGA), 24 random nucleotides, and 18 bases which match the 3' end of GAL4 (1-100). The DNA fragment encoding

GAL4(1-100)+X8 will then be generated by PCR using this oligonucleotide and the 5' sequence of *GAL4* as primers, and *GAL4(1-100)* DNA as a template. This PCR fragment will be purified by agarose gel purification, digested with the appropriate restriction enzymes, and ligated into the multiple cloning sites of the plasmid

5 pcDNA3.1/Zeo (from Invitrogen), a high level mammalian expression vector containing Zeocin resistance gene as a selective marker. This ligation reaction will be transformed into the *E. coli* strain DH5 α to generate a library of colonies containing eight random amino acids fused to *GAL4(1-100)*. These colonies will be combined into many pools (~ 100), in case we use transient transfection to screen

10 the activators (see below). The plasmids will be isolated from these pools, combined, and used to transfect the reporter cells. Theoretically, the library has to contain at least $20^8 = 2.6 \times 10^{10}$ primary colonies to cover all the possible sequences. This would be difficult to generate. Our results of yeast activating peptides, however, indicate that activating sequences occur much more frequently. Therefore,

15 we should be able to find activators by screening 10^5 primary colonies. In addition, our results also suggest that residues in human activating peptides may be similar to that of yeast. We can construct a biased library: we will fuse eight residues of F, L, P, D, and T, as these are the most common in our yeast activating peptides, in random order to *GAL4(1-100)*. We will then only need $5^8 = 3.9 \times 10^5$ to cover all

20 the possibilities in this library.

Transfection and Activator Screening

We will transfet the plasmids isolated from the random library into the EGFP-neo reporter cells using the standard methods, such as LipofectAMINE (from

25 Gibco BRL) or calcium phosphate. About 40 hours after transfection, the cells will be trypsinized and flowed through a FAC sorting machine. The cells expressing EGFP at high level can be isolated, and these cells will be replated in the medium supplemented with geneticin (G418) and Zeocin for selection of both activating plasmid and reporter expression. We will maintain these cells in the same medium

30 until individual clones form. These clones will be selected and passed as stable cell lines. In these experiments a *GAL4(1-100)* expression plasmid will be used as

negative control, and GAL4(1-100)+VP16(411-455) (pGAL-VP) as a positive control. The activating peptides will be amplified by PCR and recloned into the vector pcDNA3.1/Zeo. the resulting plasmid will be retransfected back into reporter cells to check plasmid linkage. The real activating peptides will be sequenced and 5 the stronger activators will be selected to test their effect on classical activators in squelching assay.

Alternatively, we will try to use transient transfections to screen the mammalian activating peptides. Transient assays do not rely on the integrating efficiency of the plasmid library. Hence, it may be relatively easy for us to obtain 10 the activating peptides. We will transfet the plasmids from different pools of the library and assay the EGFP reporter by FAC scan or by fluorescence microscopy. The activating plasmid pool will be retransformed into *E. coli*, and the colonies will be pooled at smaller size. The plasmids from the subpools will be transfected into 15 the reporter cells. This process will be repeated until we find a single colony of activating plasmid.

Squelching Assay

We will use transient transfection to test effects of the activators isolated on classic activator VP16. We will cotransfect pGAL-VP and a reporter plasmid with 20 or without the activating peptide plasmid into HELa cells. Here, we will use pG5ELuc containing a luciferase gene instead of EGFP-neomycin as a reporter plasmid because it is readily quantitated. We will harvest transfected cells ~40 hours after transfection and measure luciferase activity using a luminometer machine. We will also include pCMV-lacZ plasmid in our transient transfection 25 assay. pCMV-laxZ encodes a constitutively expressed β -galactosidase which will be assayed and used as an internal control to normalize transfection efficiencies. This assay will allow us to determine if the peptide activators squelch VP16.

After screening these libraries, we expect to find some strong activators that activate transcription by a mechanism different from that of classical activators. We 30 will, if necessary, randomly mutagenize the identified activator(s) at one or two positions(s), or add a few more random residues, and screen for better activators.

One advantage of using the FACS sorting is that we can set a threshold to separate the cells expressing EGFP at a level higher than that of the activator we mutagenized. This may allow us to obtain even stronger activators. Such activators will be further characterized and used in studies of sequence specific gene activation.

5

EXAMPLE 5: Three-Component Transcriptional Activation System for Identifying Protein-Protein Interactions

Materials and Methods

SYSTEM AND CONSTRUCT: Interaction assay of the three-component

10 transcriptional activation system is performed in yeast strain YW9603, which is derived from yeast strain YT6 (Himmelfarb et al., *Cell* 63:1699, 1990) by replacing GAL11 gene with a GAL11P allele (N342V) (Barberis et al., *Cell* 81:359, 1995), and integrating a reporter gene JPY169. The reporter JP169 bears two LexA binding sites 191 base pairs upstream of GAL1 TATA box, followed by LacZ gene.

15 TBP-LexA fusion is expressed from the yeast ACT1 promoter. GAL4 derivatives were described in Wu et al., *EMBO J.*, 1996 (in press), specifically, a GAL4(1-100)+(840-881) fusion gene, and derivatives deleted from the 3' end, were constructed using the polymerase chain reaction (oligonucleotide sequences available on request). These proteins were expressed in yeast from low copy number

20 ARS1/CEN4 plasmids from a fragment of the yeast actin promoter (666 bp 5' to the ATG of ACT1). All regions of plasmids that had been subjected to PCR were sequenced to ensure that the correct fusion construct had been made, and that no mutations had arisen during amplification.

SURFACE PLASMON RESONANCE SENSORCHIP PREPARATION: *In vitro* affinities

25 are measured by Surface Plasmon Resonance, as described in Wu et al., *EMBO J.*, 1996 (in press). Specifically, the dextran surface of Sensorchip CM5 was activated by two consecutive 40 μ l injections of NHS/EDC (Pharmacia) at a flow rate of 2 μ l per minute. Streptavidin (Sigma) was then coupled to the activated dextran by injecting 10 μ l of 0.1 mg/ml solution in 10 mM NaOAc, pH 4.5 at a flow rate of 2

30 μ l per minute. The excess of activated dextran was blocked by two consecutive 40 μ l injections ethanolamine at a flow rate of 2 μ l per minute. This procedure

prolonged the activation and blocking time (from the usual 7 minutes to 40 minutes) so that the negative charges on the dextran surface was greatly reduced. A 50mer DNA oligo (sequence available upon request) carrying two consensus GAL4 binding sites was synthesized with a biotin group attached to the 5' end. It was annealed to 5 its complementary oligo (without biotin) by heating to 75°C followed by slow cooling. The resulting double strand DNA carries two GAL4 binding sites and is biotinylated at one end. 10 μ l of the biotinylated DNA (6.25 μ g/ml) was injected to the streptavidin immobilized chip at a flow rate of 5 μ l per minute. The average 10 result of the procedure is that ~ 3000 RU's of streptavidin was immobilized and ~ 600 RU's of DNA was attached to the chip. After the first regeneration (by 15 washing with 10 μ l 0.1% SDS), the DNA bearing sensorchip becomes very stable and it could sustain many rounds of regeneration without significant changes in the baseline levels. This DNA bearing chip was used to capture GAL4 derivatives in such a conformation that the activating regions were uniformly presented and their 20 interactions with other proteins were studied. In control experiments, GAL80, TBP and TFIIB did not bind detectably to the DNA bearing chip (data not shown). The amine coupling method published in the BIACore manual (Pharmacia Biosensor AB, 1994) differs from ours as follows: in the published method, the activation of dextran surface by NHS/EDC, binding of ligand, and blocking of excess activated 25 dextran by ethanolamine was each performed by a single injecting of 35 μ l volume at a flow rate of 5 μ l/min. This method produced chips that, in our preliminary experiments, bound TBP and TFIIB significantly, probably because of the relatively large amount of negative charge remaining on the unactivated portion of the sensorchip.

PROTEIN-PROTEIN INTERACTIONS: The activators (GAL4 derivatives and other 30 activating regions fused to GAL4 DNA binding domain) were first passed over the DNA-bearing chip. Typically 10 μ l of 0.01 mg/ml protein solution (~ 1 μ M) in HBS (10 mM HEPES pH 7.4, 150 mM NaCl, 0.0005% Surfactant P20, Pharmacia) were injected at a flow rate of 5 μ l/min, and the DNA was saturated by the activators. This is indicated by the first increase of the RU value on the 35 sensorgrams. Various proteins to be tested (e.g., TBP) were then injected (typically

20 μ l of 1 mM solution in HBS at a flow rate of 5 μ l/min), and their binding to the activating regions was indicated by the second increase of the RU value on the sensogram. The DNA bearing chip was then regenerated by washing with 10 μ l of 0.1% SDS, a procedure that washes both proteins off the DNA, but leaves the DNA

5 bearing chip intact. The baseline of the sensorgrams always comes back to the original level after each regeneration. A different activator was then injected to the same surface at the same concentration, and the DNA was once again saturated with the activators. As a consequence the same number of the molecules of the activators was immobilized to the chip each time. The protein to be tested (e.g., TBP) was

10 once again injected and its binding to this activator was compared to that of the previous one. This comparison, we believe, is highly accurate because the exact same concentration of the same protein to be tested (e.g., TBP) was injected, and same number of molecules of activators was immobilized each time. GAL4 DNA binding domain alone was used as a negative control for each tested protein.

15 KINETIC EVALUATION: The apparent kinetic constants (k_{on} and k_{off}) of TBP, TFIIB and other tested proteins binding to various activators were the protein to be tested (e.g., TBP) was injected, followed by an injection of 10 μ l 0.1% SDS to regenerate the sensorchip. The activator was injected at the same concentration in each sensorgram, but the protein to be tested (e.g., TBP) was injected 7 different

20 concentrations in 2 fold serial increases (e.g., TBP was injected at 0.0625 μ M, 0.125 μ M, 0.25 μ M, 0.5 μ M, 1 μ M, 2 μ M and 4 μ M). All of the injections were performed at a flow rate of 5 μ l/min. A sensorgram of a blank buffer injection following the injection of the activator was subtracted from each of the 7 sensorgrams showing different concentrations of the tested proteins (e.g. TBP)

25 binding to the activator. The resulting sensorgrams corrected for the slow decay of the activators from the DNA. This correction in fact did not significantly change the calculated K_D 's. The binding kinetics of all the interactions fit well to the first order kinetics model, and the k_{on} and k_{off} was solved using linear regression algorithm. The apparent equilibrium constant K_D was obtained by dividing k_{off} with k_{on}

Results

We employed TBP and Gal4 region II' (G4RII'), as interaction partners in a three-component screen. Specifically, we fused TBP to the LexA DNA binding domain and fused G4RII' (as Gal4(840-881)) to Gal4(1-100). We introduced these 5 constructs into Gal11 and Gal11P yeast cells bearing a reporter that included two LexA binding sites upstream of a *GAL1-LacZ* reporter construct. We compared the expression levels of the *LacZ* gene in Gal11 and Gal11P cells by plate assay. Our results are presented in Table 4.

10

TABLE 4		
G4RII'-TBP Interaction Assayed in Three-Component Transcriptional Activation System		
Gal4 Derivative	<i>In vitro</i> Affinity for TBP	Blueness on X-Gal plates
(1-100) + (840-881)	$6 \times 10^6 \text{ M}^{-1}$	+++
(1-100) + (840-857)	$2 \times 10^6 \text{ M}^{-1}$	+
(1-100) + nothing	$0 \times 10^6 \text{ M}^{-1}$	-

EXAMPLE 6: Production and Characterization of TBP Mutants that Enhance Transcriptional Activation:

20 The TBP mutations N69R and V71R were isolated from screening a TBP mutant library in yeast strain YW9510, derived from JPY9 by integrating reporter gene RY131 and expressing a GAL4 derivative GAL4(1-100)+(858-881)F869A (Wu et al, *EMBO J.*, 1996, in press). TBP-encoding plasmids in darker blue colonies on X-gal plates were rescued and characterized, yielding the above mutations. β -galactosidase activity was measured in YW9510 carrying these mutant TBP's and 25 wild type TBP's.

The results are presented below in Table 5:

TABLE 5	
Transcriptional Activation by Gal4(1-100; 858-881)F869A in the Presence of TBP Mutants	
TBP derivative	β -galactosidase units
Wild-type	53
V71R	121
N69R	125

These mutations were tested in a yeast strain expressing a LexA-GAL11 fusion protein and a reporter gene carrying two LexA sites 1,200 base pairs away from the GAL11-LacZ TATA box. The results are shown below in Table 6:

TABLE 6	
Transcriptional Activation by LexA-Gal11 in the Presence of TBP Mutants	
TBP derivative	β -galactosidase units
Wild-type	13
V71R	164
N69R	192

Claims

1. A transcriptional activator comprising:
a DNA binding moiety; and
a peptide approximately 6-25 amino acids in length, which peptide is
5 covalently attached to the DNA binding domain and does not correspond to a
fragment of a naturally-occurring transcriptional activator.
2. The transcriptional activator of claim 1, wherein the peptide is approximately
8-17 amino acids in length.
10
3. The transcriptional activator of claim 1 or 2, wherein the peptide is 6, 8, 11,
or 13 amino acids in length.
15
4. A transcriptional activator comprising:
a DNA binding moiety; and
a substantially hydrophobic polypeptide between about 6 and 25 amino acids
in length, which peptide is linked to the DNA binding moiety in a manner that does
not interfere with its DNA binding activity,
the transcriptional activator being characterized by an ability, when expressed in
20 yeast cells, to activate transcription from a promoter including a recognition site for
the DNA binding moiety approximately 250-1000 basepairs upstream of the
transcription start site, optionally comprising the transcriptional activator of any one
of claims 1 to 3.
- 25 5. The transcriptional activator of claim 4, which transcriptional activator, when
expressed in yeast, does not squelch transcriptional activation by LexA-Gal4.
6. The transcriptional activator of claim 4 or 5, which transcriptional activator,
when expressed in yeast, does not squelch transcriptional activation by LexA-Gal11.
30

7. The transcriptional activator of claim 4 or claim 5, in which the DNA binding moiety comprises Gal4(1-100) and the activator, when expressed in yeast, activates transcription at least half as well as does Gal4 from a promoter containing at least one Gal4 DNA binding site approximately 250-1000 basepairs upstream of the transcription start site.
8. The transcriptional activator of any one of claims 1 to 7 wherein the peptide includes at least one aromatic amino acid.
- 10 9. The transcriptional activator of any one of claims 1 to 8, wherein the peptide does not include any basic amino acids.
10. The transcriptional activator of any one of claims 1 to 9, wherein the peptide is selected from the group consisting of LS4 (QLPPWL); LS8 (QFLDAL); LS11 (LDSFYV); LS12 (PPPPWP); LS17 (SWFDVE); LS19 (QLPDLF); LS20 (PLPDLF); LS21 (FESDDI); LS24 (QYDLFP); LS25 (LPDLIL); LS30 (LPDFDP); LS35 (LFPYSL); LS51 (FDPFNQ); LS64 (DFDVLL); LS102 (HPPPPI); LS105 (LPGCFF); LS106 (QYDLFD); LS120 (YPPPPF); LS123 (PLPPFL); LS135 (LPPPWL); LS136 (VWPPAV); LS152 (DPPWYL); LS153 (LY); LS158 (FDPFGL); LS160 (PPSVNL); LS201 (YLLPTCIP); LS202 (LQVHNST); LS203 (VLDFTPFL); LS206 (HHAFYEIP); LS212 (PWYPTPYL); LS223 (YLLPFLPY); LS225 (YFLPLLST); LS232 (FSPTFWAF); LS241 (LIMNWPTY), each of these peptides extended by Gal4 residues 96-100, and each of these peptides extended by residues corresponding to Gal4 96-100 except that one or both of Gal4 residues 99 and 100 has been substituted with a different amino acid.
11. A method of identifying novel transcriptional activators, the method comprising steps of:
 - providing a collection of synthetic oligonucleotides of random sequence,
 - 30 which oligonucleotides are approximately 18-24 base pairs in length;

linking oligonucleotides from the collection to a nucleic acid encoding a polypeptide with DNA binding activity, thereby producing a library of artificial transcriptional activator genes;

expressing encoded hybrid proteins from the library of artificial transcriptional activator genes; and

identifying hybrid proteins that activate transcription.

12. The method of claim 11 further comprising a step of identifying hybrid proteins that, when expressed in yeast cells, do not squelch transcriptional activation by Gal4.

13. A hybrid protein that activates transcription, the hybrid protein being produced by the method of either of claim 11 or claim 12.

15 14. A method of activating transcription in a cell, the method comprising: providing to the cell a transcriptional activator of any one of claims 1 to 10 or claim 12a under conditions that the transcriptional activator will bind to a DNA site in the cell and activate transcription; and

identifying those transcriptional activators that:

20 i) stimulate transcription at least half as effectively as does a known transcriptional activator linked to the same DNA binding moiety and assayed on the same reporter gene; and
ii) do not squelch transcriptional activation by acidic activators in yeast.

25 15. In a di-hybrid protein-protein interaction assay the improvement that comprises utilizing Gal11 as a transcriptional activation domain.

16. A method of identifying protein-protein interactions, the method comprising: providing a first fusion comprising a DNA binding domain fused to a library 30 of DNA fragments;

providing a second fusion comprising a target protein fused to a polypeptide comprising a region of Gal4 with which Gal11P interacts;
introducing the first and second fusion in a cell including Gal11P; and
identifying library members that interact with the target protein by identifying
5 those cells in which transcription is activated.

17. An isolated protein that is a derivative of TBP, which derivative is selected from the group consisting of TBP N69R and TBP V71R.

10 18. A method of altering transcriptional activation, comprising:
introducing into a cell a TBP derivative selected from the group consisting of
TBP N69R and TBP V71R.


15 19. Use of Gal11 as a transcriptional activation domain in a protein-protein
interaction trap assay.

20. Use of a derivative of TBO for altering transcriptional activation of a cell,
wherein the TBP derivative is selected from the group consisting of TBP N69R and
TBP V71R.

20 21. Use of a fusion protein for identifying protein-protein interactions wherein the
fusion protein comprises a target protein fused to a polypeptide comprising a region
of Gal4 with which Gal11P interacts.

25 22. Use of a transcriptional activator according to any one of claims 1 to 10 to
activate transcription in a cell whilst substantially not squelching other transcriptional
activators.


Transcriptional Activation Depends on Peptide Sequence



Construct	β -gal activity
GAL4(1-881)	2300
GAL4(1-100)	2
GAL4(1-100)+ + L I C Y P L P T	4400
+ I P L Y L T C P	100
	17

FIGURE 1


Residues of the GAL4 DNA Binding Domain Contribute to Peptide Activation



Construct	β-gal. activity
GAL4(1-881)	2800
GAL4(1- 91 ALLTGLFVQD 100)	2
GAL4(1- 100 ALLTGLFVQD + <u>8mer</u> YLLPTCIP	4400
ALLTGLFVQ□ + YLLPTCIP	120
ALLTGLFV□D + YLLPTCIP	450
ALLTGLF□QD + YLLPTCIP	3
ALLTGL□VQD + YLLPTCIP	2
ALLTG□FVQD + YLLPTCIP	3
ALLTGLFVQA + YLLPTCIP	4200
ALLTGLFVAD + YLLPTCIP	3800
ALLTGLFAQD + YLLPTCIP	100
ALLTGLAVQD + YLLPTCIP	30

FIGURE 2

The Peptide Activates Transcription When Fused to the PHO4 DNA Binding Domain








Figure 4

The Peptide Activates Transcription *In Vitro*



LS201p (ng): 0 1 5 30 100



E4 ext. →
product

1 2 3 4 5

FIGURE 5




FIGURE 6




FIGURE E

DI-HYBRID SCREENS
EMPLOYING
Gal-11





FIGURE 8

Cells Bearing GAL11P Mutation



Cells Bearing Wildtype GAL11




FIGURE 9

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.